ASSURE Wearable ECG vs Tempus ECG-AF
AI Verdict
Choose ASSURE Wearable ECG if…
Choose the ASSURE Wearable ECG if you require continuous, real-time heart rate monitoring and immediate data capture for at-risk cardiac patients. This tool is ideal for managing patients who need ongoing surveillance for arrhythmias, post-intervention monitoring, or those experiencing intermittent symptoms that necessitate prompt detection and clinician alerts.
View ASSURE Wearable ECG →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify older patients (65+) at an increased risk of developing new-onset atrial fibrillation within the next year. This AI-powered algorithm is best suited for screening asymptomatic individuals using a standard 12-lead ECG to inform earlier intervention strategies and targeted follow-up.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ASSURE Wearable ECG | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | The ASSURE system is intended for use by a patient during their normal daily activities primarily in the home or community setting, but also hospitals, medical clinics, healthcare facilities and transport. | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ASSURE Wearable ECGTool A, the ASSURE Wearable ECG, is designed as a wearable device with a mobile application and a comfortable SensorFit Garment, suggesting a patient-centric and intuitive experience for continuous monitoring outside of a clinical setting. Tool B, Tempus ECG-AF, is a software solution integrated into existing healthcare facility systems, which, while efficient for clinicians, does not offer the same direct patient usability for ongoing data collection.
Clinical Value
Tempus ECG-AFTool B, Tempus ECG-AF, offers a distinct clinical value by using AI to predict the risk of new-onset Atrial Fibrillation within 12 months for a specific patient demographic from a standard 12-lead ECG. This predictive capability enables proactive intervention and earlier identification. While Tool A provides valuable continuous monitoring and real-time alerts, Tool B's ability to forecast future risk from a single test represents a unique and high-impact clinical insight.
Pricing & Value
Tempus ECG-AFTool B, Tempus ECG-AF, clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, providing transparency and a clear path for financial viability for healthcare providers. Tool A only states 'contact for pricing,' offering no public information on cost or potential reimbursement, making its value proposition less transparent from a financial perspective.
Enterprise Readiness
TieBoth tools demonstrate strong foundational enterprise readiness, being FDA-cleared, HIPAA compliant, and having Business Associate Agreements (BAAs) in place. Tool B, as a software solution integrated into existing facility systems, may offer a smoother IT integration for large enterprises. However, Tool A's comprehensive platform including a wearable, mobile app, and cloud platform is also designed for enterprise-level remote patient management, making it difficult to definitively choose a winner without more specific integration details.
Innovation
Tempus ECG-AFTool B, Tempus ECG-AF, showcases significant innovation through its AI-based algorithm that predicts the future risk of Atrial Fibrillation from a single 12-lead ECG, leveraging a vast dataset of over 1.5 million ECGs. This predictive capability for a future event from a static diagnostic test represents a cutting-edge application of AI in cardiology. While Tool A innovates in wearable design and motion artifact filtering for continuous monitoring, Tool B's predictive analytics for future risk is arguably more groundbreaking.
Support & Docs
TieNeither the provided structured facts nor general web searches for either product prominently feature dedicated public support portals or extensive documentation that would allow for a clear distinction between the two. Both companies likely offer support to their customers, but public-facing information is insufficient to declare a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ASSURE Wearable ECG | Tempus ECG-AF |
|---|---|---|
| Name | ASSURE Wearable ECG | Tempus ECG-AF |
| Primary Function/Purpose | Non-therapeutic device for continuous heart rate monitoring and data collection, integrated into a digital healthcare platform for at-risk cardiac patients. | AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Key Technology/Algorithm | ASSURE Detection Algorithm with Quad Channel Processingu2122, Adaptive Patient Intelligenceu2122 for filtering motion artifacts. | AI-based algorithm for 12-lead ECG analysis, trained on over 1.5 million ECGs from over 500,000 patients. |
| Target Patient Population | At-risk cardiac patients. | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Specialties | Cardiology | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring ASSURE Wearable ECG and Tempus ECG-AF.